Coherus BioSciences, Inc. 4
4 · Coherus BioSciences, Inc. · Filed Nov 12, 2014
Insider Transaction Report
Form 4
Richards Christos
Director
Transactions
- Conversion
Series B Preferred Stock
2014-11-12−12,672→ 0 total→ Common Stock (12,672 underlying) - Exercise of In-Money
Common Stock, $0.0001 par value
2014-11-12$1.67/sh+26,505$44,184→ 26,505 total - Other
Common Stock, $0.0001 par value
2014-11-12−2,956→ 23,549 total - Conversion
Common Stock, $0.0001 par value
2014-11-12+39,991→ 63,540 total - Conversion
Common Stock, $0.0001 par value
2014-11-12+12,672→ 76,212 total - Exercise of In-Money
Warrant to Purchase Common Stock
2014-11-12−26,505→ 0 totalExercise: $1.67→ Common Stock (26,505 underlying) - Exercise of In-Money
Series B Preferred Stock
2014-11-12$0.02/sh+429$7→ 12,673 total→ Common Stock (429 underlying) - Conversion
Series A Preferred Stock
2014-11-12−39,991→ 0 total→ Common Stock (39,991 underlying) - Conversion
Common Stock, $0.0001 par value
2014-11-12+2,624→ 78,836 total - Exercise of In-Money
Warrant to Purchase Series B Preferred Stock
2014-11-12−429→ 0 totalExercise: $0.02→ Series B Preferred Stock (429 underlying) - Other
Series B Preferred Stock
2014-11-12−1→ 12,672 total→ Common Stock (1 underlying) - Conversion
Series C Preferred Stock
2014-11-12−2,624→ 0 total→ Common Stock (2,624 underlying)
Footnotes (6)
- [F1]Immediately prior to the closing of the IPO, the warrant automatically net exercised by its terms into Common Stock, which allowed the holder to pay the exercise price of the warrant by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.
- [F2]The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis upon the closing of Issuer's initial public offering.
- [F3]The warrant is immediately exercisable.
- [F4]The warrant expires upon the consummation of the Issuer's initial public offering to the extent not previously exercised.
- [F5]The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock have no expiration date.
- [F6]Immediately prior to the closing of the IPO, the warrant automatically net exercised by its terms into Series B Preferred Stock, which allowed the holder to pay the exercise price of the warrant by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.